Merck & Co., Inc. (MRK)
Why Did Merck Stock Rise 65%?
Merck stock (NYSE: MRK) has gained over 65% in value since early January 2021 – jumping from levels of $70 then to around $115 now – vs. an increase of about 50% for the S&P 500 over this period.
Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.
What's Wrong With Merck's Stock?
Merck's business is growing, but the stock's gains have been modest this year. The drug manufacturer remains heavily reliant on Keytruda, which accounts for nearly half of its revenue.
Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma
MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.
Merck's Change To Profit Guidance Provides An Opportunity
Merck's reduced profit guidance is primarily due to recent acquisitions, but the company remains strong with potential for future growth, especially in 2024. Keytruda continues to be a key revenue driver, contributing 45% of Merck's total revenue, with potential for sustained double-digit growth. Strategic acquisitions, like Acceleron, are broadening Merck's pipeline, with new drugs like Winrevair showing promising revenue growth.
Merck (MRK) Advances But Underperforms Market: Key Facts
In the most recent trading session, Merck (MRK) closed at $118.45, indicating a +0.84% shift from the previous trading day.
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.
Merck scraps two late-stage trials of cancer drug Keytruda
Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial failures for the blockbuster drug.
Why Is Merck (MRK) Up 3.8% Since Last Earnings Report?
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate
Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a rare blood disorder.
Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?
MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.
Merck (MRK) Falls 10% in 3 Months: Should You Buy the Dip?
Declining estimates and the recent price drop make investors skeptical about holding Merck's (MRK) stock.
